Endothelial barrier is everything BRIEFLY IN FINNISH ABOUT US DRUG TARGETS PIPELINE NEWS INVESTOR RELATIONS CONTACT Pipeline HomePipelinePartners Commercialisation Strategy Faron has decided to initiate selective commercial collaborations with Faron drug candidates in limited territories but maintain full marketing and sales rights in Traumakine®´s main markets in the Company. The main market (Europe, USA) licensing deals will be considered after having the Phase III trial in respect of Traumakine® treatment of ARDS completed and data from this trial has become available. The Company thinks that this strategy will serve the best interest of the Faron shareholders and allows flexible approach in the future. The specialty pharma company Maruishi Pharmaceutical Co., Ltd. based in Osaka, Japan has been licensed Traumakine® in return for up to €5 million in development payments. Maruishi has carried out the Phase II clinical trial in Japan in respect of Traumakine® with positive top-line results and is planning the next pivotal clinical trial to be conducted there. Maruishi will cover all the development costs in Japan in respect of Traumakine®. Faron is to receive a share of Maruishi´s net profits of Traumakine® through milestones, royalties and other payments. To date, Faron has received €2.3 million in milestone payments pursuant to its agreement with Maruishi and is due to receive up to an additional €2.7 million subject to certain key development milestones being met. CMS collaboration in Greater China is based on strategic agreements, according to which the Group (CMS and closely related development company A&B) has assets with Traumakine® rights in Mainland China, Hong Kong, Macao and Taiwan. The CMS Group also covers all territorial development costs. Faron is entitled to a profit per treatment and low double digit royalties above a certain minimum treatment price. A&B is a shareholder of Faron. Pharmbio Korea, based in Seoul, has been licensed Traumakine® to develop and commercialise the treatment of ARDS in Korea. Faron is paid an initial signing fee of €750,000 and is entitled to receive additional, development based milestones. In addition, Pharmbio will pay Faron one third of Traumakine® profits, representing a double digit royalty on net sales, depending on end user pricing, and has agreed to cover development costs for Traumakine® in Korea. Additionally, Faron will provide European approval material for Pharmbio to obtain market authorisation in Korea and will also supply Traumakine drug product to Pharmbio at an agreed transfer price. PIPELINE › PROGRAMMES › TRAUMAKINE CLINICAL PROGRAMME › THERAPEUTIC AREAS › PARTNERS PRINT SHARE FOLLOW US ON LINKED IN Faron Pharmaceuticals Joukahaisenkatu 6, Intelligate FIN-20520 TURKU Finland Phone: +358 2 469 5151 Fax: +358 2 469 5152 Email: info@faronpharmaceuticals.com Subscribe now Keep updated with Company news and events. YOUR EMAIL ADDRESS